Juno Therapeutics (JUNO) CEO Bishop: Second JCAR015 Patient with Brain Swelling has Died - Conf. call
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
SunTrust Robinson Humphrey Downgrades Juno Therapeutics (JUNO) to Hold
November 25, 2016 6:48 AM ESTSunTrust Robinson Humphrey downgraded Juno Therapeutics (NASDAQ: JUNO) from Buy to Hold with a price target of $25.00 (from $48.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL was placed on clinical hold for the second time.
The analyst sees reduced visibility and increased... More
Juno Therapeutics (JUNO) PT Lowered to $34 at Maxim Group
November 23, 2016 1:51 PM ESTMaxim Group analyst Jason McCarthy lowered his price target on Juno Therapeutics (NASDAQ: JUNO) to $34.00 (from $50.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL (Acute Lymphoblastic Leukemia) was placed on clinical hold for the second time. The firm maintained a Buy rating.
McCarthy highlighted:
The ROCKET study evaluating JCAR015 in no-option Adult ALL (Acute Lymphoblastic Leukemia) was placed on clinical hold for the second time. Two more patients died due to treatment-related neurotoxicity (cerebral edema), the same cause of death observed in July when ROCKET was... Morebluebird bio (BLUE) Falls 5% on Juno Clinical Hold
November 23, 2016 8:42 AM ESTbluebird bio (NASDAQ: BLUE) is trading down after peer Juno Therapeutics, Inc. (Nasdaq: JUNO) announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute... More
Juno Therapeutics (JUNO) Sinks 40% as Trading Resumes after Clinical Hold
November 23, 2016 8:33 AM ESTJuno Therapeutics (NASDAQ: JUNO) resumed trading down 40% after the company announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the ROCKET trial. The clinical... More
Juno Therapeutics (JUNO) to Resume Trading at 8:30AM ET after Clinical Hold Announced
November 23, 2016 8:05 AM ESTJuno Therapeutics (NASDAQ: JUNO) set to resume trading at 8:30AM ET after it voluntarily placed on hold the Phase II clinical trial of JCAR015
... MoreKite Pharma (KITE) on Watch as Juno Trial Placed on Clinical Hold
November 23, 2016 8:02 AM ESTKite Pharma (NASDAQ: KITE) on watch as Juno Therapeutics, Inc. (Nasdaq: JUNO) announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic... More
Juno Therapeutics (JUNO) Halted for News Release
November 23, 2016 8:01 AM ESTJuno Therapeutics (NASDAQ: JUNO) Halted for News Release
... MoreJuno Therapeutics (JUNO) JCAR015 Phase II ROCKET Trial Placed on Clinical Hold
November 23, 2016 8:01 AM ESTJuno Therapeutics, Inc. (Nasdaq: JUNO) announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the ROCKET trial. The clinical hold was initiated after two patients suffered cerebral edema... More